Matrix Metalloproteinase 3 Genotype

Two people can care for their teeth the same way and still get different amounts of bone loss around their teeth. One reason may be a common DNA variation in MMP3. MMP-3 is short for matrix metalloproteinase-3. It is an enzyme that helps break down the support tissue between cells.

This test reads that variation from cells in your saliva. It is a fixed genotype, not a saliva MMP-3 protein level. Some of the studies below measured MMP-3 protein in blood, gum fluid, saliva, or tissue. Those are related dynamic measurements. They are not the same test.

The result won't change over your lifetime. Its clinical status is still research-grade: there are human association studies and plausible mechanisms, but no guideline-backed result that tells you what will happen. Use it as risk context. It can make you more alert to gum inflammation, coronary risk, and rheumatoid arthritis severity if the rest of your history points that way.

What This Test Actually Reads

The test looks at the 5A/6A site in the promoter of MMP3. A promoter is the gene's volume control. At this spot, you carry a run of five DNA A's or six DNA A's. You inherit one copy from each parent, so the possible results are 5A/5A, 5A/6A, and 6A/6A.

That one extra A can matter. In older adults, one study found that skin samples from 5A/5A carriers had about four times the MMP3 gene expression seen in 5A/6A carriers, while 6A/6A carriers had about half as much. That is tissue gene expression, not the saliva genotype itself. The allele difference is inflammation-dependent: in unstimulated cells the 5A and 6A promoters look similar, and the higher 5A transcription mainly shows up once cells are inflamed. The genotype is the fixed setting; the protein level still changes by tissue, inflammation, sex, and disease state.

MMP-3 breaks down the body's support material between cells and can switch on MMP-1, MMP-8, and MMP-9. Some breakdown is normal. Too much can make tissue fragile. Too little can favor buildup. The heterozygote often looks like the middle setting in vascular studies, but that doesn't make it a guarantee of lower risk.

Why the Middle May Matter

The tempting mistake is to treat one allele as good and the other as bad. The human data don't fit that. The 5A allele has been linked in several studies to myocardial infarction and plaque instability. The 6A/6A genotype has been linked to more flow-limiting coronary narrowing and, in some rheumatoid arthritis cohorts, worse joint damage, though other RA studies point the opposite way. In older adults at low cardiovascular risk, 5A/6A carriers had less aortic stiffness than either homozygote.

So this is not a good-result/bad-result gene. It is a bias in tissue remodeling. The useful question is whether your result adds weight to a pattern already showing up in your gums, arteries, joints, or family history.

Gum Disease

The periodontal evidence is the most direct for the mouth, but it is still mixed. Studies of saliva and gum-crevice fluid measure MMP-3 protein, not this genotype. They show the enzyme is present in oral fluids and tends to rise with periodontitis. In one 51-person study, salivary MMP-3 fell by week 3 after deep cleaning alongside less bleeding and shallower pockets.

The genotype evidence is less settled. A 2015 meta-analysis found the 6A allele was linked to lower periodontitis risk in several small case-control studies. A 2016 meta-analysis that pooled MMP gene variants found the 5A allele linked to higher chronic periodontitis susceptibility. A 2024 meta-analysis of five chronic-periodontitis studies found no overall association, though signals differed by genotyping method and smoking. That makes the useful read narrow: 5A/5A may justify closer periodontal surveillance, especially if you smoke or already show early pocketing, but it doesn't diagnose future gum loss.

Recent Iranian studies point the same way for chronic periodontitis and peri-implantitis, while a Turkish study found higher MMP-3 in diseased gum fluid but no genotype link after adjustment. Allele frequency and disease definitions matter.

Heart Attack and Coronary Disease

The cardiovascular evidence is split. In 1,240 people undergoing coronary angiography, 6A/6A carriers had more arteries with major stenosis. Stenosis is plaque narrowing that builds slowly. Among those with coronary disease, 5A/5A carriers had about double the odds of past myocardial infarction compared with 6A/6A carriers, and 5A/6A carriers were intermediate. The same paper interpreted this as two failure modes: 6A/6A tending toward more narrowing, 5A toward less stable plaque.

Meta-analyses do not make this a clinical heart-risk test. A 2010 meta-analysis found no overall coronary-disease difference between 5A carriers and 6A/6A carriers, with possible ancestry differences. A 2023 meta-analysis found a small overall association with coronary artery disease, strongest in East Asian studies. So the result should not outrank ApoB, Lp(a), blood pressure, smoking, diabetes, or imaging. It can change how much attention you pay to those measurements.

For stroke risk itself, meta-analyses of MMP3 5A/6A are essentially null, so this is not a stroke-risk test. The strongest treatment-related signal is GenHAT. It followed 21,309 hypertensive adults for about 4.6 years and found no independent MMP3 genotype effect on stroke after adjustment. It did find a drug-by-genotype signal: 6A/6A carriers randomized to lisinopril had about a third higher stroke risk than 6A/6A carriers randomized to chlorthalidone, while 5A/5A carriers on lisinopril had lower stroke rates. This needs replication before it changes a prescription.

Rheumatoid Arthritis

If you already have rheumatoid arthritis, the MMP3 5A/6A data are directionally conflicting. One 254-person study found higher Larsen scores in 6A/6A carriers than in other genotypes and higher serum proMMP-3. Serum proMMP-3 is a blood protein level, not this saliva DNA result. Other cohorts point the other way: one study linked 5A/5A to faster radiographic progression, and another linked a specific MMP1-MMP3 haplotype that included the 5A allele to joint destruction that varied by disease stage. Both alleles have been implicated depending on the cohort and outcome measured.

The genotype does not diagnose rheumatoid arthritis, and larger genome-wide studies have not made MMP3 a routine RA-prognosis marker. The best-established inherited RA signal is still HLA-DRB1. The HLA-DRB1 shared epitope is an inherited RA risk pattern. In one study, 6A/6A seemed to add risk on top of it.

Cancer Signals Are Weak and Subtype-Specific

Older and newer meta-analyses disagree on cancer susceptibility. A 2014 meta-analysis of 41 studies found no overall cancer-risk link but reported subgroup signals for gastrointestinal cancers and Asian cohorts. A 2023 update with 63 studies found small increased risks overall and in some cancer subtypes. A separate metastasis meta-analysis suggested lower metastasis odds in 6A-containing genotypes, especially in breast cancer. None of this makes MMP3 genotyping a cancer-screening test.

One-Time Result, Long-Term Use

You do not need to repeat this test. Your DNA sequence at this spot is fixed. The value comes from changing the cadence of other checks, not from watching this result move.

Start with the phenotype. If your gums have ever shown deep pockets, bleeding, bone loss, or implant inflammation, get a full periodontal charting exam and consider staying on a six-month or shorter dental interval, especially with 5A/5A. If you have cardiovascular risk factors, check ApoB and Lp(a). Lp(a) is usually a one-time test; ApoB is the number to recheck when treatment or risk changes. If joint swelling or morning stiffness appears, check rheumatoid-factor and anti-CCP antibodies and consider rheumatology evaluation. If you already have hypertension, use the GenHAT finding as a discussion point, not a reason to change medication on your own.

When the Result Can Mislead

A genotype test tells you what letters you carry at the site the assay reads. It does not tell you everything about MMP3 or whether disease is active today.

• Panel coverage: the assay reads the 5A/6A promoter site, not every variant in MMP3. A negative result for this variant does not rule out rarer changes in the same gene.
• Assay naming: -1171 and -1612 can refer to the same 5A/6A promoter insertion-deletion, depending on numbering. Make sure the report matches the MMP3 5A/6A site, also called rs3025058 or rs35068180.
• Ancestry: allele frequencies differ by population, and many studies come from specific cohorts. A finding in one group may not carry the same weight in another.
• VUS calls: this single-site test should return 5A/5A, 5A/6A, or 6A/6A. A broader DNA test may report an MMP3 variant of uncertain significance. That is a different result and usually should not drive action by itself.
• Somatic versus germline DNA: tumor sequencing and some blood DNA tests after a stem-cell or bone-marrow transplant can reflect acquired or donor DNA. This test is meant to read the inherited DNA you were born with, so tell the lab about transplant history.
• Sample quality: saliva and buccal samples need enough of your cells. If the sample is thin or collected too close to eating, drinking, brushing, or mouthwash, the lab may not get a clean read.
• Direct-to-consumer versus clinical genotyping: a consumer SNP-array report may not cover this insertion-deletion or may call it less reliably than a targeted clinical assay. If two reports disagree, confirm with a clinical method.

What to Do With an Unexpected Result

If you come back 5A/5A, treat it as a reason to be less casual about gums and plaque risk, not as a diagnosis. Get periodontal charting if you don't have recent probing depths. Check ApoB and Lp(a); Lp(a) is mostly inherited, while ApoB is the number you can change. If you smoke, quitting matters even more because smoking worsens both gum breakdown and plaque rupture risk.

If you come back 6A/6A, think more about slow buildup and, if RA runs in your family, joint symptoms. A coronary artery calcium score can be useful if you are over 40 or have other risk factors. Joint swelling, prolonged morning stiffness, or unexplained hand and foot pain should move you toward rheumatoid-factor and anti-CCP testing and a rheumatology visit. Heterozygotes do not get a free pass; they just don't point as strongly in either direction.

Family members may share the same version, but the exact odds depend on both parents' genotypes. Each child gets one of your two MMP3 copies. Full siblings can share zero, one, or two copies. If your result is 5A/5A or 6A/6A and early heart attack, aggressive gum disease, or rheumatoid arthritis runs in the family, first-degree relatives may want their own test.